Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the tumour necrosis factor superfamily of cell death-inducing ligands, which were discovered and cloned by Wiley et al. in the mid-1990s. It has obtained infinite attention as the greatest candidate for cancer therapy because it selectively induces apoptosis in numerous human cancer cells but not in normal cells. However, the development of resistance to TRAIL restricts its utilization in the treatment of ovarian cancer. Here, we showed that B cell lymphomallymphoma-2(Bcl-2) and cellular Fas-associated death domain-like interleukin-1 converting enzyme inhibitory protein (c-FLIP), two anti-apoptotic proteins, were over-expressed in a large portion of ovarian cancer tissues, as judged by immunohistochemistry. These proteins may play critical roles as the key points in the regulation of resistance to TRAIL. We hypothesized that downregulation of Bcl-2 and c-FLIP might overcome TRAIL resistance in ovarian cancer cells. The aim of this study was to explore the apoptosis-inducing effects of TRAIL, alone or in combination with Si-Bcl-2 or Si-c-FLIP or both, on OVCA432 ovarian cancer cells.